The Mitochondrial Electron Transport Chain: A Brief Introduction
The mitochondria are the primary energy-producing organelles of eukaryotic cells. Their principal product is adenosine triphosphate (ATP) — the universal currency of cellular energy — generated through a process called oxidative phosphorylation.
The electron transport chain (ETC) is the series of protein complexes embedded in the inner mitochondrial membrane that carries out this process. Electrons harvested from nutrients enter the chain and pass through four complexes (I through IV), releasing energy at each step. That energy is used to pump protons across the inner membrane, creating an electrochemical gradient that drives ATP synthesis through a fifth complex (ATP synthase, or Complex V).
Complex IV is cytochrome c oxidase (CCO). It is the terminal enzyme in the electron transport chain — the final protein complex through which electrons pass before combining with oxygen to form water. CCO catalyzes the last step of oxidative phosphorylation and is rate-limiting for the entire process. When CCO activity is high, mitochondrial ATP production is high. When CCO is inhibited — by nitric oxide, for example, which binds competitively to its active site — the entire chain slows, and cellular energy production declines.
Dr. Tiina Karu's work, beginning in the 1980s and continuing through the 2000s, established that cytochrome c oxidase contains chromophores — light-absorbing molecules — in its two copper centers (CuA and CuB) and two heme iron centers (heme a and heme a3). These chromophores absorb light in the red and near-infrared spectrum, with distinct absorption peaks corresponding to the enzyme's different redox states.
In her seminal 1999 review published in the Journal of Photochemistry and Photobiology B, Karu synthesized the evidence for CCO as the primary photoacceptor in the red and near-infrared range, proposing a mechanistic chain: photon absorption by CCO chromophores → changes in enzyme redox state → increased electron transfer efficiency → enhanced mitochondrial membrane potential → increased ATP synthesis → downstream cellular signaling.
This mechanism was not purely theoretical. Karu and colleagues directly measured ATP production, oxygen consumption, and proton pumping in cell cultures exposed to red and NIR light, and showed dose-dependent increases consistent with enhanced CCO activity. The biological effects of light were traceable, step by step, to a specific enzyme at a specific location in the cell.
Dr. Michael Hamblin of Harvard Medical School — arguably the most prolific contemporary researcher in photobiomodulation — has extended Karu's foundational work into a comprehensive mechanistic framework. In reviews published in Photochemistry and Photobiology and the Journal of Biophotonics, Hamblin has described the downstream consequences of CCO photoactivation in considerable detail.
Beyond direct ATP enhancement, CCO photoactivation appears to trigger a cascade of mitochondrial signaling events including changes in mitochondrial membrane potential, production of reactive oxygen species (ROS) at sub-damaging levels (which function as intracellular signals), release of nitric oxide from its binding site on CCO (which has been competitive with electron transfer), and activation of transcription factors including NF-κB, which regulate the expression of hundreds of downstream genes.
Hamblin has noted that the biphasic nature of photobiomodulation — where both too little and too much light produces suboptimal effects — is consistent with the dose-response characteristics of mitochondrial ROS signaling, where low-level ROS generation is stimulatory and high-level ROS generation is damaging. The therapeutic window for PBM corresponds, in this framework, to the range of light doses that stimulate beneficial mitochondrial signaling without causing oxidative damage.
Cytochrome c oxidase absorbs light across a broad range, but its absorption spectrum has distinct peaks. In the red range, primary peaks have been identified at approximately 620-680nm. In the near-infrared range, peaks have been identified at approximately 760nm and 820-840nm. These spectral characteristics are important for understanding which light wavelengths are most biologically active — and why red light therapy devices designed around these specific wavelengths may be more effective than broadband light sources.
The 660nm wavelength commonly used in red light therapy devices falls within the primary absorption band of the oxidized (inactive) form of CCO — the form found in cells under oxidative stress or with impaired mitochondrial function. The 830nm and 850nm wavelengths commonly used in near-infrared applications fall within the absorption band of the reduced form. This spectral complementarity means that both wavelengths can stimulate CCO activity, but through slightly different mechanisms and with potentially different applications.
→ Know your exact number. The Mitolux at-home Vitamin D blood test — processed by Omega Quant clinical laboratory — delivers your precise 25(OH)D level in ng/mL, by email, in under two weeks. Order at mitolux.com/test for $49.
Disclaimer: Mitolux is for general wellness and self-care use. Individual experiences vary. This content is for informational purposes only and is not medical advice. Mitolux is not intended to diagnose, treat, cure, or prevent any disease.